MCL coexpression mm9:358

Phase1 CAGE Peaks

	Short description
Mm9::chr11:69778995..69779012,+	p1@Cldn7
Mm9::chr11:69779228..69779243,+	p7@Cldn7
Mm9::chr11:99294264..99294277,-	p@chr11:99294264..99294277 -
Mm9::chr14:56636802..56636807,+	p1@Mcpt1
Mm9::chr15:101829917..101829924,+	p@chr15:101829917..101829924 +
Mm9::chr17:88039711..88039730,+	p@chr17:88039711..88039730 +
Mm9::chr17:88039785..88039803,+	p@chr17:88039785..88039803 +
Mm9::chr17:88040769..88040816,+	p@chr17:88040769..88040816 +
Mm9::chr17:88045479..88045492,+	p@chr17:88045479..88045492 +
Mm9::chr17:88045589..88045600,+	p@chr17:88045589..88045600 +
Mm9::chr17:88045610..88045632,+	p@chr17:88045610..88045632 +
Mm9::chr17:88045641..88045653,+	p@chr17:88045641..88045653 +
Mm9::chr17:88049772..88049788,+	p@chr17:88049772..88049788 +
Mm9::chr17:88049792..88049806,+	p@chr17:88049792..88049806 +
Mm9::chr17:88049831..88049870,+	p@chr17:88049831..88049870 +
Mm9::chr17:88049905..88049920,+	p@chr17:88049905..88049920 +
Mm9::chr18:27288460..27288463,-	p@chr18:27288460..27288463 -
Mm9::chr19:4042230..4042242,-	p2@Gm3934 p2@Gstp2
Mm9::chr5:135462690..135462703,+	p@chr5:135462690..135462703 +
Mm9::chr7:107413155..107413177,+	p1@Gpx2-ps1
Mm9::chr7:30043559..30043594,-	p@chr7:30043559..30043594 -
Mm9::chr8:4354144..4354155,+	p@chr8:4354144..4354155 +

Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

---

GO ID	GO name	FDR corrected p-value
GO:0005923	tight junction	0.00195887011784764
GO:0043296	apical junction complex	0.00195887011784764
GO:0016327	apicolateral plasma membrane	0.00195887011784764
GO:0005911	intercellular junction	0.00408132352187767
GO:0016338	calcium-independent cell-cell adhesion	0.0107773595554197
GO:0030054	cell junction	0.017508089013351
GO:0006749	glutathione metabolic process	0.0243513269385111
GO:0004364	glutathione transferase activity	0.0257847023406538

Relative expression of the co-expression cluster over median <br>Analyst:

---

"{{{coexpression_dpi_cluster_scores_median}}}" is not a number.

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>

---

Cell Type

Ontology term	p-value	n

Uber Anatomy

Ontology term	p-value	n

Disease

Ontology term	p-value	n

TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

---

Novel motifs

JASPAR motifs

Motifs	-log10(p-value)
{{{tfbs_overrepresentation_jaspar}}}